Tumor Regression Induced by Intratumor Therapy with a Disabled Infectious Single Cycle (DISC) Herpes Simplex Virus (HSV) Vector, DISC/HSV/Murine Granulocyte-Macrophage Colony-Stimulating Factor, Correlates with Antigen-Specific Adaptive Immunity1

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Journal of Immunology

• Publication date

  2002-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4049/jimmunol.168.7.3512PMID 11907113
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Genetically modified tumour cells for cancer immunization

  2001cited by this paper
• Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents.

  2001cited by this paper
• Consequences of Cell Death

  2000cited by this paper
• Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: Persistent transgene expression despite antibody generation

  2000cited by this paper
• Characterization and transduction of a retroviral vector encoding human interleukin-4 and herpes simplex virus-thymidine kinase for glioma tumor vaccine therapy

  2000cited by this paper
• Ovarian cancer gene therapy: repeated treatment with thymidine kinase in an adenovirus vector and ganciclovir improves survival in a novel immunocompetent murine model.

  2000cited by this paper
• Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes.

  2000cited by this paper
• Consequences of cell death: exposure to necrotic tumor cells

  2000cited by this paper
• Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors.

  2000cited by this paper
• Systemic Antitumor Immunity in Experimental Brain Tumor Therapy Using a Multimutated, Replication-Competent Herpes Simplex Virus

  1999cited by this paper
• Tumor-induced immune dysfunction

  1999cited by this paper
• Immunogenicity of apoptotic cells in vivo: role of antigen load, antigen-presenting cells, and cytokines.

  1999cited by this paper
• Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor cells generates systemic antitumor immunity.

  1999cited by this paper
• Chimeric papillomavirus virus‐like particles induce a murine self‐antigen‐specific protective and therapeutic antitumor immune response

  1999cited by this paper
• Oncolytic therapy using a mutant type-1 herpes simplex virus and the role of the immune system.

  1999cited by this paper
• Natural adjuvants: Endogenous activators of dendritic cells

  1999cited by this paper
• Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12.

  1999cited by this paper
• Disabled Infectious Single-Cycle Herpes Simplex Virus as an Oncolytic Vector for Immunotherapy of Colorectal Cancer

  1999cited by this paper
• Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas

  1999cited by this paper
• Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells.

  1999cited by this paper
• Selective MHC expression in tumours modulates adaptive and innate antitumour responses

  1999cited by this paper
• Cells and cytokines in immunotherapy and gene therapy of cancer.

  1999cited by this paper
• The role of CD4+ T cell responses in antitumor immunity.

  1998cited by this paper
• Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs

  1998cited by this paper
• Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function.

  1998cited by this paper
• Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma

  1998cited by this paper
• Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells.

  1998cited by this paper
• Decreased antigen presentation by dendritic cells in patients with breast cancer.

  1997cited by this paper
• Tumor-peptide-pulsed dendritic cells isolated from spleen or cultured in vitro from bone marrow precursors can provide protection against tumor challenge

  1997cited by this paper
• Cytokines, tumour-cell death and immunogenicity: a question of choice.

  1997cited by this paper
• Cancer vaccines based on the identification of genes encoding cancer regression antigens.

  1997cited by this paper
• Dendritic Cells Retrovirally Transduced with a Model Antigen Gene Are Therapeutically Effective against Established Pulmonary Metastases

  1997cited by this paper
• Herpes simplex virus type 1-mediated up-regulation of IL-12 (p40) mRNA expression. Implications in immunopathogenesis and protection.

  1996cited by this paper
• T‐Cell Immunotherapy of Tumors by Adoptive Transfer of Cytotoxic T Lymphocytes and by Vaccination with Minimal Essential Epitopes

  1995cited by this paper
• Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses

  1995cited by this paper
• Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1.

  1995cited by this paper
• Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens.

  1994cited by this paper
• Protective Vaccination Against Primary And Recurrent Disease Caused By Herpes Simplex Virus (HSV) Type 2 Using A Genetically Disabled HSV-1

  1994cited by this paper
• MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses.

  1994cited by this paper
• Adenovirus-mediated gene transfer for cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung.

  1994cited by this paper
• Tolerance, danger, and the extended family.

  1994cited by this paper
• Infiltration of S-100 protein positive dendritic cells and peritoneal recurrence in advanced gastric cancer.

  1992cited by this paper
• Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor

  1992cited by this paper
• New strategies for active immunotherapy with genetically engineered tumor cells.

  1992cited by this paper

• Desarrollo de vacunas recombinantes marcadoras multiserotipo frente al virus de la lengua azul

  2017cites this paper
• Gene therapy in the treatment of human cancer

  2017cites this paper
• Recombinant vaccines against bluetongue virus.

  2014cites this paper
• Identification and immunogenicity of two new HLA-A*0201-restricted CD8+ T-cell epitopes on dengue NS1 protein.

  2012cites this paper
• Engineered herpes simplex virus vectors for antitumor therapy and vaccine delivery

  2011cites this paper
• A Kunjin replicon vector encoding granulocyte macrophage colony-stimulating factor for intra-tumoral gene therapy

  2009cites this paper
• CTL responses to Leishmania mexicana gp63‐cDNA vaccine in a murine model

  2009cites this paper
• Immunostimulatory cancer chemotherapy using local ingenol-3-angelate and synergy with immunotherapies.

  2009cites this paper
• Molecular and cellular expression of novel genes associated with breast cancer

  2009influential citation
• Proteomic analysis of biomarkers associated with immunotherapy in murine tumour models

  2009cites this paper
• Vaccination strategies for malignant diseases

  2008cites this paper
• Investigating the potential of the Metastasis Associated Antigen 1 (MTA1) for cancer immunotherapy in a murine model

  2007influential citation
• Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte–macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus

  2007cites this paper
• Expression of human immunodeficiency virus type 1 tat from a replication-deficient herpes simplex type 1 vector induces antigen-specific T cell responses.

  2006cites this paper
• The role of CD4+ T cell help in cancer immunity and the formulation of novel cancer vaccines

  2006cites this paper
• Amplicons as vaccine vectors.

  2006cites this paper
• Species-specificity of a murine immunocontraceptive utilising murine cytomegalovirus as a gene delivery vector.

  2005cites this paper
• Screening New Drugs for Immunotoxic Potential: III. Assessment of the Effects of Selective and Nonselective COX-2 Inhibitors on T-Cell-Dependent Antibody and Natural Killer Cell Responses in the Rat

  2005cites this paper
• Immunotherapeutic potential of DISC-HSV and OX40L in cancer

  2005influential citation
• Combined Dendritic Cell Cryotherapy of Tumor Induces Systemic Antimetastatic Immunity

  2005cites this paper
• Peptide immunisation of HLA-DR–transgenic mice permits the identification of a novel HLA-DRβ1*0101– and HLA-DRβ1*0401–restricted epitope from p53

  2005cites this paper
• Contemporary Cancer Research

  2005cites this paper
• Development of Oncolytic Replication-Competent Herpes Simplex Virus Vectors

  2005cites this paper
• Immunity to tumour antigens.

  2005cites this paper
• Regulation of CTL responses to MHC‐restricted class I peptide of the gp70 tumour antigen by splenic parenchymal CD4+ T cells in mice failing immunotherapy with DISC–mGM‐CSF

  2005cites this paper
• Immunotherapy of Cancer by Dendritic Cell-Targeted Gene Transfer

  2005cites this paper
• Trafficking of tumor peptide‐specific cytotoxic T lymphocytes into the tumor microcirculation

  2004cites this paper
• Herpes simplex virus‐based vectors

  2004cites this paper
• Evaluation of the potential immunotoxicity of 3-monochloro-1,2-propanediol in Balb/c mice. I. Effect on antibody forming cell, mitogen-stimulated lymphocyte proliferation, splenic subset, and natural killer cell activity.

  2004cites this paper
• Anti-tumour therapeutic efficacy of OX40L in murine tumour model.

  2004cites this paper
• Escape from immunotherapy: possible mechanisms that influence tumor regression/progression

  2004cites this paper
• Increased survival and decreased tumor size due to intratumoral injection of ethanol followed by administration of immature dendritic cells.

  2003cites this paper
• Cancer immunotherapy: an embarrassment of riches?

  2003cites this paper
• International conference: Progress in vaccination against cancer (PIVAC) 2002, Nottingham, UK

  2003cites this paper
• Disabled infectious single cycle herpes simplex virus (DISC‐HSV) is a candidate vector system for gene delivery/expression of GM‐CSF in human prostate cancer therapy

  2003cites this paper
• Characterisation of tumour-associated antigens in colon cancer

  2002cites this paper
• Progress in vaccination against cancer (PIVAC) 2002

  2002cites this paper